Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion

The primary objective of this investigation is to compare the efficacy of two different antithrombotic strategies after percutaneous LAA occlusion with a Watchman device on the prevention of silent cerebral embolism.

Inclusion Criteria:AF patients over 18 years oldPatients had undergone left atrial appendage occlusion with WATCHMAN device and confirmed no significant peri-device leak or DRT at the 45-day CTPatients have a history of ischemic thromboembolic events or have CHA2DS2-VASc score ≥3Exclusion Criteria:Patients with an indication of long-term antiplatelet therapy other than LAAO at the time of enrollment (eg, ACS, Intracranial vascular stenosis≥75%)Absolute contraindications to OACAbsolute contraindications to anti-platelet therapyContraindications to MR or unwilling to receiving MRPatients with clinical thromboembolicor major bleeding events within 45 days after LAA occlusion